Comment on: Pharmacokinetics and Safety of Recombinant Human Interleukin-1 Receptor Antagonist GR007 in Healthy Chinese Subjects

  • Nuggehally R. SrinivasEmail author
Letter to the Editor

Dear Editor,

Interleukin-1 (IL-1), a proinflammatory cytokine observed in the serum and synovial fluid in rheumatoid arthritis (RA) patients, has been implicated in the debilitating pathology that ultimately leads to the severe impairment and destruction of articular cartilage in RA patients [1]. This observation led to the development and approval of anakinra, a IL-1 receptor antagonist which blocks the biological activity of the IL-1 endogenously secreted in human tissues and organs in RA patients by binding to the IL-1 receptor site [2, 3]. The effectiveness of anakinra has been shown not only in RA patients but also in patients with other neonatal inflammatory diseases [4, 5].

In this context, GR007, a novel recombinant human interleukin-1 receptor antagonist with amino-acid structural features consistent with those of anakinra [6], is being developed as a means to competitively restrict the interaction of the endogenous IL-1 in both chemotherapy-induced neutropenia and...


Compliance with Ethical Standards


No funding was used to prepare this letter.

Conflict of interest

The author has no conflict of interest.


  1. 1.
    Deleuran BW, Chu CQ, Field M. Localization of interleukin-1 alpha, type 1 interleukin-1 receptor and interleukin-1 receptor antagonist in the synovial membrane and cartilage/pannus junction in rheumatoid arthritis. Br J Rheumatol. 1992;31(12):801–9.CrossRefGoogle Scholar
  2. 2.
    Cohen S, Hurd E, Cush J. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002;46(3):614–24.CrossRefGoogle Scholar
  3. 3.
    Fleischmanna RM, Schechtman JB, Bennett R. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: a large, international, multicenter, placebo-controlled trial. Arthritis Rheum. 2003;48(4):927–34.CrossRefGoogle Scholar
  4. 4.
    Mansky MD, Natalie J, Dailey MD. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med. 2006;355(6):581–92.CrossRefGoogle Scholar
  5. 5.
    Neven B, Marvillet I, Terrada C. Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem infammatory disease/chronic infantile neurologic, cutaneous, articular syndrome. Arthritis Rheum. 2010;62(1):258–67.CrossRefGoogle Scholar
  6. 6.
    Xie R, Zhang Y, Zhao N, Zhou S, Wang X, Han W, Yu Y, Zhao X, Cui Y. Pharmacokinetics and safety of recombinant human interleukin-1 receptor antagonist GR007 in healthy Chinese subjects. Eur J Drug Metab Pharmacokinet. 2019;44(3):353–60.CrossRefGoogle Scholar
  7. 7.
    Qian L, Xiang D, Zhang J. Recombinant human interleukin-1 receptor antagonist reduces acute lethal toxicity and protects hematopoiesis from chemotoxicity in vivo. Biomed Pharmacother. 2013;67(2):108–15.CrossRefGoogle Scholar
  8. 8.
    Xiang D, Guo Y, Zhang J. Interleukin-1 receptor antagonist attenuates cyclophosphamide-induced mucositis in a murine model. Cancer Chemother Pharmacol. 2011;67(6):1445–53.CrossRefGoogle Scholar
  9. 9.
    Wang X, Gao J, Qian L. Exogenous IL-1Ra attenuates intestinal mucositis induced by oxaliplatin and 5-fluorouracil through suppression of p53-dependent apoptosis. Anticancer Drugs. 2015;26(1):35–45.Google Scholar
  10. 10.
    Wang X, Zhu S, Qian L. IL-1Ra selectively protects intestinal crypt epithelial cells, but not tumor cells, from chemotoxicity via p53-mediated upregulation of p21(WAF1) and p27(KIP1). Pharmacol Res. 2014;82:21–33.CrossRefGoogle Scholar
  11. 11.
    Barbhaiya RH, Knupp CA, Tenney J, Martin RR, Weidler DJ, Pittman KA. Safety, tolerance, and pharmacokinetics of cefepime administered intramuscularly to healthy subjects. J Clin Pharmacol. 1990;30(10):900–10.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Innovation and TechnologyJubilant Life SciencesNoidaIndia

Personalised recommendations